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OBJECTIVES: A post-hoc sub-group analysis provides evidence that lacosamide
when used in conjunction with a non-sodium-channel blocking AED ismore effec-
tive than when used in combination with another sodium-channel blocking AED.
In order to allow patients earlier subsidised access to lacosamide (via the Pharma-
ceutical Benefits Scheme), a cost-effectiveness analysiswas conducted.METHODS:
Three large randomised, placebo controlled trials (SP667, SP754 and SP755) were
meta-analysed. More specifically, the analysis examined lacosamide used in con-
junction with a non-sodium channel AED (the sub-group) vs. lacosamide used in
conjunction with at least one sodium channel AED (the complement group). A deci-
sion tree (TreeAge) economic model reported the “cost per incremental 50% re-
sponder”. Lacosamide was utilised in the compliment group as a proxy for other
(similarly priced) adjunctive AED treatment. RESULTS: The meta-analysis, com-
pared those trial patients meeting the proposed PBS indication (the sub-group) to its
complement. More patients in the subgroup achieved a 50% reduction in seizure
frequency compared to the complement (51.1% vs. 34.7% respectively). Based on the
test of effect modification, there is a statistically meaningful effect modification
within the proposed subgroup (p0.03). The modelled incremental cost effective-
ness ICER, lacosamide (sub-group) costs $3064 per additional patient who achieves
at least a 50% reduction in seizures compared to the compliment. CONCLUSIONS:
A reimbursed listing on the PBS was sought which would limit the use of lacos-
amide to a refractory group and then only in combination with non-sodium AEDs.
Probabilistic sensitivity analysis was undertaken which showed that the PBAC
could be confident in that 68% of the outcomes are below $4000/responder. This
supported the robustness of the ICER. The analysis could have been strengthened
had it been based on a pre-specified analysis (and therefore randomised accord-
ingly), rather than on a post-hoc analysis.
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OBJECTIVES: To evaluate societal and economic benefits of self-administrated in-
jection of sumatriptan succinate compared to hospital-administrated one in the
treatment of acute severemigraine in Japan setting.METHODS:A cost-utility anal-
ysis (cost per QALY gained) by simulatingwith a 5-stateMarkovModel is conducted
from the societal perspective. Parameters incorporated into the model were taken
from literatures and the PMS of subcutaneous sumatriptan carried out in Japan.
Cost components incorporated into the model consist of migraine-related medical
costs, medicines, and transportation costs for traditional health care provider and
emergency room visits, calculating with Japan insurance-based medical fee
scheme for medical techniques and national health insurance price of medicines.
To assess robustness of a base case, univariate sensitivity analyses using tornado
diagram and probabilistic analysis using 10000-time Monte Carlo simulation were
performed. TreeAge Pro 2007 was used for the data analysis. RESULTS: At the base
case, it was deemed that use of self-administrated injection was less costly and
more effectiveness than hospital-administrated one. Univariate analyses revealed
that probability of onset of attack per week was identified as a cost driver. The
probabilistic analysis suggested that if willingness to pay on decision-making in
Japan setting was set at 5,000,000 JPY per QALY gained, approximately 100% of
probabilitywere obtained dominant consequences in a hypothetical cohort. There-
fore, it was demonstrated robustness of the base case analysis, retrospectively.
CONCLUSIONS: Thus, the aforementioned result suggested that the use of self-
administrated injection dominated hospital-administrated one irrespective of a
high initial price of self-administrated injection.
PND13
OLD AND NEW ANTIEPILEPTIC DRUGS UTILIZATION IN IRAN
Gharibnaseri Z, Kheirandish M, Kebriaeezadeh A
Tehran University of Medical Sciences, Tehran, Iran
OBJECTIVES:To evaluate the 10 year utilization trends of antiepileptic drugs (AEDs)
in Iran. METHODS: Annual pharmaceutical sales data were acquired from the
Ministry ofHealth (MOH). To express data, Anatomical Therapeutic Chemical (ATC)
classification and Defined Daily Dose (DDD) as described by WHO collaborating
centre for drug statistics methodology were used. DDD/1000 Inhabitants/Day (DID)
was the main unit for measuring drug sales and N03 was considered as AEDs here.
RESULTS: Between 2000 and 2010, the total consumption of antiepileptic drugs
increased by 49.85%, and reached 8.7 DDD/1000 inhabitants/day in 2010.Within the
studied ten years, the consumption of old AEDs increased by 9.6% (6.37 DDD/1000
inhabitants/d ay in 2010), while in the case of new AEDs the increase was 11432%
(2.37 DDD/1000 inhabitants/day). CONCLUSIONS: A significant shift can be seen in
the consumption of newAEDs. This change is partly due to the improved efficacy of
these drugs compared to the older types and referable to new indications to some
extent.
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OBJECTIVES:Multiple sclerosis (MS) is a costly disease that affects adults. There are
very few studies evaluating the impact of high disease activity (HDA) on costs and
resource use using real world data. This study aims to compare demographics, cost
and resource utilization of MS patients with high and low annual relapses.
METHODS: A retrospective cross-sectional study was done using MarketScan®
commercial claim and Medicare database, 2009. Patients included had at least one
ICD-9 for MS (340.XX), were older than 18 years, and had continuous enrolment for
one year. HDA was defined as having two relapses annually, and relapse was de-
fined according to Chastek 2010 algorithm. Bivariate analysis were conducted to
compare HDA patients and other MS patients on patient characteristics, resource
utilization and costs (chi-square test for categorical variables and t-test for contin-
uous variables). RESULTS: A total of 22,170 patients met the study criteria. 94.58%
(N20,969) had less than two relapses and 5.42% (N1,201) had more than two
relapses in 2009. HDA patients were younger (49 vs. 52 years) and less likely to be
employed (50.54% vs. 56.12%). MS symptoms were more frequent in HDA group
including pain (54.87% vs. 39.55%), balance and coordination problems (24.23% vs.
10.72%) and fatigue (24.06% vs. 12.64%). HDA patients had more all cause and MS-
specific hospitalizations (26.39% vs. 12.59% and 15.24% vs. 1.62%) and ER visits
(39.88% vs.23.39% and 21.15% vs. 7.75%) compared to non-HDApatients. Mean total
cost (excluding DMT drug costs) for the HDA group was US$30,637 compared with
US$14,240 for the non-HDA group. p 0.0001 for all. CONCLUSIONS: Patients with
two or more relapses annually have high resource utilization and are more costly.
Two or more relapse annually seem to be indicative of high disease activity, how-
ever, amore robust algorithm needs to be validated to study such population using
claims database.
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OBJECTIVES: Chronic migraine (CM), defined as headache on at least 15 days per
month, with at least 8 days of migraine, is a sub-type of chronic daily headache
associated with significant quality of life (QoL) impairment. Clinical studies dem-
onstrate that botulinum toxin type A (BTX-A, 155-195U injected at specific head
and neck areas) results in clinically significant improvements in headache symp-
toms and QoL for CM patients. This study was conducted to obtain patient narra-
tives describing how response to BTX-A has benefited them in their daily lives.
METHODS: CM patients undergoing treatment with BTX-A were recruited via a
letter from their neurologist for in-depth interviews. The participants were ten
female chronic migraineurs who had suffered from migraines for 7-35 years, and
had received BTX-A treatment for 6 months to 5 years. RESULTS: For all partici-
pants, CMwas severely debilitating across all aspects of their lives including work/
study, family/personal relationships and social interactions. Some patients re-
ported prior symptoms of depression including suicidal ideation. The participants
had previously trialled numerous acute and prophylactic treatments but had ex-
perienced lack of efficacy, intolerance and rebound headaches from medication
overuse. Following treatment with BTX-A, participants reported reduced fre-
quency, severity and duration ofmigraines and headaches, increased dayswithout
acute medication intake, and improved response to simple analgesics. Personal
benefits included the ability to return to work or study, care for their children,
engage in social activities and take more active roles in the community. Partici-
pants felt that public reimbursement of BTX-A for CM would have a number of
positive outcomes including reduced financial stress of treatment for themselves
and their families, as well as potential cost reductions to the health care system
from decreased use of other medications and less hospitalisations and/or doctor
visits. CONCLUSIONS: CM patients responding to BTX-A prophylaxis report im-
proved symptoms and multiple QoL benefits.
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OBJECTIVES: Many studies as well as clinical experience indicate that moderate-
to-severe psoriasis is an emotionally and socially disabling disease. Themajority of
these studies, however, have been conducted in western countries, including Eu-
rope andNorth America. This study aimed to determine the burdens of psoriasis in
patients with psoriasis living in the Asia Pacific countries.METHODS:A systematic
literature search was conducted to identify evidence published between January
1990 and February 2012 evaluating the disease burdens, quality of life, and epide-
miology of psoriasis in Asia Pacific. RESULTS: Forty-five publications from China,
Hong Kong, India, Malaysia, Singapore, South Korea, and Taiwan were identified.
This literature demonstrated that psoriasis produces substantial impairments in
patients’ quality of life (QOL), and the level of impairment is dependent on the
patients’ disease severity. Across the retrieved literature, severely impaired quality
of life was observed in 19-39% of patients. The Dermatology Life Quality Index
(DLQI), a commonly used instrument to assess skin disease-specific QOL showed a
mean score of 6-20, indicating a moderate to very large effect of psoriasis on QOL.
Patients experienced difficulty in social life, daily activities, and reduced work
productivity. A higher Psoriasis Area and Severity Index (PASI) score (greater dis-
ease severity) was correlated with more impaired QOL. Psoriasis patients also suf-
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